Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2018, Article ID 6703963, 14 pages
https://doi.org/10.1155/2018/6703963
Research Article

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

1RTI Health Solutions, 2nd Floor, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester M20 2LS, UK
2Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
3Eli Lilly GmbH, Koelblgasse 8, 1030 Vienna, Austria
4RTI Health Solutions, 1440 Main Street, Suite 310, Waltham, MA 02451, USA
5Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK

Correspondence should be addressed to Lisa M. Hess; moc.yllil@m_asil_sseh

Received 7 September 2017; Accepted 29 November 2017; Published 26 March 2018

Academic Editor: Valerae O. Lewis

Copyright © 2018 Santiago Zuluaga-Sanchez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Misra, N. Mistry, R. Grimer, and F. Peart, “The management of soft tissue sarcoma,” Journal of Plastic, Reconstructive & Aesthetic Surgery, vol. 62, no. 2, pp. 161–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Penel, C. Nisse, S. Feddal, and E. Lartigau, “Epidemiology of soft tissue sarcomas in adults,” La Presse Médicale, vol. 30, no. 28, pp. 1405–1413, 2001. View at Google Scholar
  3. American Cancer Society, Cancer Facts and Figures 2015, American Cancer Society, Atlanta, GA, USA, 2015, , http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
  4. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Coindre, P. Terrier, L. Guillou et al., “Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas,” Cancer, vol. 91, no. 10, pp. 1914–1926, 2001. View at Publisher · View at Google Scholar
  6. National Cancer Institute, “SEER stat fact sheet: all cancer site,” 2015, https://seer.cancer.gov/statfacts/html/all.html. View at Google Scholar
  7. National Comprehensive Cancer Network, “Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 2,” , 2017, https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. View at Google Scholar
  8. S. Verma and V. Bramwell, “Dose-intensive chemotherapy in advanced adult soft tissue sarcoma,” Expert Review of Anticancer Therapy, vol. 2, no. 2, pp. 201–215, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. van Glabbeke, A. T. van Oosterom, J. W. Oosterhuis et al., “Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 150–157, 1999. View at Publisher · View at Google Scholar
  10. V. Karavasillis, B. M. Seddon, S. Ashley, O. Al-Muderis, C. Fisher, and I. Judson, “Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients,” Cancer, vol. 112, no. 7, pp. 1585–1591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Minchom, R. L. Jones, C. Fisher et al., “Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma,” Sarcoma, vol. 2010, Article ID 264360, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Judson, J. Verweij, H. Gelderblom et al., “Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial,” The Lancet Oncology, vol. 15, pp. 415–423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. C. W. Ryan, O. Merimsky, M. Agulnik et al., “PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma,” Journal of Clinical Oncology, vol. 34, no. 32, pp. 3898–3905, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. R. S. Benjamin, P. H. Wiernik, and N. R. Bachur, “Adriamycin: a new effective agent in the therapy of disseminated sarcomas,” Medical and Pediatric Oncology, vol. 1, no. 1, pp. 63–76, 1975. View at Publisher · View at Google Scholar · View at Scopus
  15. US Food and Drug Administration, “LARTRUVO (olaratumab) injection, for intravenous use in the US,” 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526087.htm. View at Google Scholar
  16. European Medicines Agency, “Summary of opinion (initial authorization). Lautrvo,” 2016, http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004216/WC500212882.pdf. View at Google Scholar
  17. W. D. Tap, R. L. Jones, B. A. Van Tine et al., “Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial,” The Lancet, vol. 388, no. 10043, pp. 488–497, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. Eli Lilly and Company, “A study of doxorubicin plus olaratumab (LY3012207) in participants with advanced or metastatic soft tissue sarcoma (ANNOUNCE),” in ClinicalTrials.gov,, 2016, NLM Identifier: NCT02451943, https://clinicaltrials.gov/ct2/show/NCT02451943. View at Google Scholar
  19. B. M. Seddon, J. Whelan, S. J. Strauss et al., “GeDDiS: a prospective randomized controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29),” Journal of Clinical Oncology, vol. 33, no. 15, p. 10500, 2015. View at Google Scholar
  20. B. Bui-Nguyen, I. Ray-Coquard, C. Chevreau et al., “High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial,” Annals of Oncology, vol. 23, no. 3, pp. 777–784, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Judson, J. A. Radford, M. Harris et al., “Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 37, no. 7, pp. 870–877, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Bertwistle, Y. D’Yachkova, A. Vickers et al., “Comparative efficacy and safety of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta-analysis,” in Proceedings of the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Poster PCN24, Vienna, Austria, October-November 2016.
  24. I. Judson, J. Verweij, H. Gelderblom et al., “European Organisation and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group. Results of a randomised phase III trial (EORTC 62012) of single-agent doxorubicin versus doxorubicin plus ifosfamide as first-line chemotherapy for patients with advanced, soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group,” in Proceedings of the 2012 Connective Tissue Oncology Society Annual Meeting, Prague, Czech Republic, November 2012.
  25. D. M. Eddy, W. Hollingworth, J. J. Caro, J. Tsevat, K. M. McDonald, and J. B. Wong, “Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7,” Value Health, vol. 15, no. 6, pp. 843–850, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. NICE Decision Support Unit, Evidence Synthesis TSD series, 2013, http://scharr.dept.shef.ac.uk/nicedsu/technical-support-documents/evidence-synthesis-tsd-series/.
  27. J. Amdahl, S. C. Manson, R. Isbell et al., “Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United Kingdom,” Sarcoma, vol. 2014, Article ID 481071, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Nemeth and Á. Vincziczki, “The role of half-cycle correction in the models used for health technology assessment,” Value in Health, vol. 16, no. 7, pp. A592–A593, 2013. View at Publisher · View at Google Scholar
  29. M. R. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein, Cost-Effectiveness in Health and Medicine, Oxford University Press, New York, NY, USA, 1996.
  30. Micromedex Solutions, RedBook 2016, 2016, http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/redbook.ModifyRedBookSearch.
  31. Essential RBRVS, A Comprehensive Listing of Rbrvs Values for Cpt and Hcpcs Codes, OptumInsight Inc., Salt Lake City, UT, USA, 2016.
  32. Eli Lilly and Company, Economic Value Tool. Additional Analyses of the JGDG Study Data for the Economic Model. Data on File, 2016.
  33. Eli Lilly and Company, “JGDG clinical study report,” 2015, I5B-IE-JGDG Clinical Study Report, Data on file. View at Google Scholar
  34. N. Latimer, “NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials—extrapolation with patient level data,” 2013, http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. View at Google Scholar
  35. Centers for Disease Control and Prevention, National Vital Statistics Report. Deaths: Final Data for 2013, 2013, http://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm.
  36. N. R. Latimer and K. R. Abrams, “NICE DSU Technical Support Document 16: adjusting survival time estimates in the presence of treatment switching,” 2014, http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD16_Treatment_Switching.pdf. View at Google Scholar
  37. N. R. Latimer, K. R. Abrams, P. C. Lambert et al., “Adjusting survival time estimates to account for treatment switching in randomized controlled trials—an economic evaluation context: methods, limitations, and recommendations,” Medical Decision Making, vol. 34, no. 3, pp. 387–402, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Bureau of Labor Statistics, “U.S. city average; item: medical care; base period: 1982–84 = 100. Not seasonally adjusted,” 2016, http://data.bls.gov/cgi-bin/surveymost?cu. View at Google Scholar
  39. Agency for Healthcare Research and Quality, “Healthcare Cost and Utilization Project (HCUP),” 2013, http://hcupnet.ahrq.gov/. View at Google Scholar
  40. A. Briggs, “Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty,” Value in Health, vol. 8, no. 1, pp. 1-2, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. B. S. Woods, N. Hawkins, and D. A. Scott, “Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial,” BMC Medical Research Methodology, vol. 10, no. 1, p. 1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Lorenzo, L. M. Hess, S. Nicol, R. Parikh, S. D. Candrilli, and J. A. Kaye, “Advanced soft-tissue sarcoma–related treatment patterns and outcomes in elderly patients in the United States,” in Proceedings of the 21st Annual Meeting of the Connective Tissue Oncology Society, Lisbon, Portugal, November 2016.
  43. P. Reichardt, M. Leahy, X. García del Muro et al., “Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study,” Sarcoma, vol. 2012, Article ID 740279, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. T. E. Delea, J. Amdahl, H. R. Nakhaipour et al., “Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada,” Current Oncology, vol. 21, no. 6, pp. e748–e759, 2014. View at Publisher · View at Google Scholar · View at Scopus